TABLE 1
FROM:
Altered expression of topoisomerase II
contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation
T Asano, K Nakamura, H Fujii, N Horichi, T Ohmori, K Hasegawa, T Isoe, M Adachi, N Otake and Y Fukunaga
BACK TO ARTICLETable 1. IC50 against MX2 and etoposide, adriamycin, and vincristine with or without indomethacin, 5-Aza-2'-deoxycytidine (5AZ) treatment
| MX2 (nM) | Etoposide (nM) | Adriamycin (nM) | Vincristine (nM) |
Carboplatin ( M)
| |
|---|---|---|---|---|---|
| K562/P | 30 4 | 104 | 203 | 2.02.1 | 205.1 |
| K562/P with indomethacin | 287 | 95 | 183 | 1.82.0 | ND |
K562/P with 2 
M 5AZ | 285 | 85 | ND | ND | ND |
| K562/P with 10
M 5AZ | 296 | 74 | 15.011.0 | 1.82.9 | 224.8 |
| K562/MX2 | 20023*
| 9415*
| 15020*
| 2.31.8 | 186.0 |
| K562/MX2 with indomethacin | 19050*
| 9025*
| 10025*
| 1.81.0 | ND |
| K562/MX2 with 2
M 5AZ | 5012a
| 105a
| ND | ND | ND |
| K562/MX2 with 10
M 5AZ | 469a
| 85a
| 13010.7 | 2.01.0 | 20.54.8 |
| K562/ADM | 289.3 | 8.23.0 | 25050*
| 20.28.1*
| 216.8 |
| K562/ADM with indomethacin | ND | ND | 5050**
| 53**
| ND |
| K562/ADM with 10
M 5AZ | 308.8 | 9.32.5 | 10020.8a
| 5.02.8a
| 205.0 |
ND=not done.
IC50 was calculated from cytotoxicity against various drugs.
Data were averages.d. from five independent experiments.
* P<0.05, cytotoxicity in K562/P vs K562/MX2, or K562/ADM cells.
** P<0.05, cytotoxicity in K562 cells with vs without indomethacin treatment.
a Cytotoxicity in K562 cells with vs without 5AZ treatment.
